PS Miner launches the world's first "XRP Liquid Mining": AI-driven multi-asset cloud mining unlocks the next generation of passive income
Investors can mine XRP, BTC, ETH, DOGE, etc. in real time for only $12.
LONDON, United Kingdom, July 02, 2025 (GLOBE NEWSWIRE) -- As the cryptocurrency market heats up and the price of XRP approaches the $5 mark, PS Miner is redefining the way investors earn mining rewards. The company has officially launched 'Ripple Liquidity Mining', the world's first AI-driven multi-asset cloud mining library, which enables users to mine multiple cryptocurrencies simultaneously and dynamically reallocate computing power to optimize real-time returns. With the official launch of Liquidity Mining, users can mine XRP, BTC, ETH, DOGE and other assets with a fully automated cryptocurrency income strategy based on market trends, profit opportunities and network difficulty. Without any technical setup or hardware, even first-time investors can start earning a stable daily income with an investment of only $12.
Why 'Liquidity Mining' will change passive crypto income
Unlike the traditional mining model that locks users into a single asset or static contract, liquidity mining uses PS Miner's proprietary AI income engine AURA for real-time dynamic adjustments. AURA tracks network-wide variables such as price fluctuations, mining difficulty, block rewards, and energy costs, and immediately reallocates computing power to the highest-yielding assets.
PS Miner CEO said: 'Liquidity mining is like an autopilot for your crypto income. Whether XRP rises or Bitcoin's hash rate fluctuates, our system will reallocate in real time, so your funds are always used where it matters most.'
Main features of PS Miner liquidity mining:
XRP sees surge in investor demand ahead of potential breakout
Analysts currently estimate that the probability of an XRP ETF being approved by early Q4 is greater than 95%, which could trigger a massive influx of institutional capital.
PS Miner Chief Market Strategist noted: 'PS Miner's XRP liquidity mining comes at the perfect time. Investors want diversified upside exposure without taking direct market risk - and this product delivers exactly that.'
Get started in three easy steps:
The display of some contract benefits is as follows:
For more information about the contract, please visit: https://psminer.com/project
About PS Miner
Founded in 2018, PS Miner is a global leader in cloud-based cryptocurrency mining and AI-driven DeFi solutions. The platform supports mining of XRP, BTC, ETH, DOGE, LTC, and SOL, providing low-risk, high-reward crypto income opportunities to over 7 million users worldwide. Join PS Miner to create the future of decentralized finance.
Contact information
Official website: https://psminer.com/
Company email: [email protected]
Disclaimer: The information provided in this press release does not constitute an investment solicitation, nor does it constitute investment advice, financial advice, or trading recommendations. Cryptocurrency mining and staking involve risks and the possibility of losing funds. It is strongly recommended that you perform due diligence before investing or trading in cryptocurrencies and securities, including consulting a professional financial advisor.
Name: Amy Wilson Email: [email protected] Job Title: manager
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Entrepreneur
43 minutes ago
- Entrepreneur
Life After London
Opinions expressed by Entrepreneur contributors are their own. You're reading Entrepreneur United Kingdom, an international franchise of Entrepreneur Media. London is known as the epicentre of UK innovation - a glittering magnet for entrepreneurs, investors and talent alike. The city's sprawling start-up ecosystem pulses with opportunity: networking events, venture capital firms, accelerators, and a dense community of like-minded disruptors. But beneath the surface, a quiet revolution is unfolding across the North, in cities like Manchester, where founders are challenging the assumption that success means being based in the capital. The story of these northern start-ups is not one of scarcity or compromise, but of strategic choice and unexpected advantages. For founders like Harvey Lowe, co-founder of Arcube, a travel sector start-up and Jana Stella, founder of NeuWave Technologies - both residents of Sister, Manchester's £1.7bn innovation district - the decision to build outside London has been liberating. Sister is fast becoming one of the UK's leading innovation districts, providing a fertile ecosystem for ambitious start-ups to thrive beyond the capital. Lowe explains: "For a lot of companies, they are located in London to be closer to other start-ups, suppliers, clients, etc. However, operating in London comes with significantly higher costs, which can be challenging for start-ups - especially when a London base isn't essential. For us – operating in the travel sector - being located in the capital isn't critical for reaching customers or prospects as we often travel to international events to meet airline companies." Manchester offers Arcube benefits that might be overlooked by a capital-centric mindset. "We're linked very closely with the university, and are able to tap into great graduate and higher education talent pools, which would be harder to connect to given the expanse of the ecosystem in London," Lowe says. That local connection extends to suppliers too. "We also see that a surprising number of our suppliers are actually based in Manchester, Leeds and the general north. It's great to meet these people in-person which wouldn't happen if we were down South." Stella echoes these advantages from a highly specialised sector. "Our sector requires a niche skillset (in wave modelling and oceanography) where the speciality really lies outside of London. Being in Manchester means we can tap into our technical network easily. We've also really benefitted from local initiatives for office space and funding." Cost efficiency is another critical factor: "It's definitely helped from a cost perspective. Building a start-up already requires close monitoring of expenditure, so the funding outside of London stretches much further." Both founders challenge the myth that location limits access to capital and opportunity. "People assume being outside London means you have less access to opportunity, capital, and talent. The reality for us is that we're less distracted by the noise, and we can work with a leaner team without compromising on quality," Lowe says. Stella adds, "It's industry dependent, but for us it hasn't been the case. Sure, a lot of our investment is London based, but it's only a train ride away. Our customers are all over the British coastlines." For Lowe, the quality of life is tangible: "I only have a 25 minute 'commute' (walk) to the office in the morning given that the city is so walkable!" Despite occasional questions about location - "People outside the UK sometimes ask if we're based in London" - it's never really a concern. "We are two hours away from London if we have to be there for a meeting or event." Freedom from the London bubble is the real prize. "Building outside the capital gives us more freedom. We're able to make decisions without being caught up in the noise or trends that make up the London scene. There's less pressure to follow what everyone else is doing," Lowe says. Minor inconveniences like "slightly longer travel times" don't slow progress. "We've got all the access to capital, talent, and opportunity we need. The trade-off is worth it and we aren't looking back." Alongside the technical and operational advantages championed by Lowe and Stella, Rachel Morgan-Trimmer, founder of Firebird - a Manchester-based neurodivergent consultancy - highlights a more intangible but equally crucial benefit: community. "People always say the North is friendlier but it really makes an impact when it comes to networking, helping other people out, etc." For Morgan-Trimmer, this warmth isn't just anecdotal; it's an essential pillar for building a business rooted in inclusivity and connection. As a neurodivergent entrepreneur, she also appreciates practical lifestyle differences. "Travelling about is a bit easier, partly because it's less crowded and city centres are more concentrated." Morgan-Trimmer challenges another pervasive myth about location and opportunity. "They think you 'have' to be in London to get anywhere or do anything. I actually do a lot of work in London and it doesn't make a difference to them (or my other clients) where I'm based. I can do Manchester to London and back in a day. I don't think there are fewer opportunities in the North than there are in London." On the question of feeling underestimated because of her location, Morgan-Trimmer is unequivocal. "No. In this day and age, I find that people don't really care where you're based. In fact, many of my clients don't even know until I mention it!" The freedom this founder finds outside London is both professional and personal. "I love London, don't get me wrong, but having grown up down south, I definitely prefer living and working in Manchester. I find the culture here to be friendly, supportive and a bit more direct – which obviously is perfect for a neurodivergent entrepreneur!" The new geography of opportunity What unites these founders is a shared rejection of London as a prerequisite for innovation. Instead, they embrace the strategic advantages of their location, supported by strong local ecosystems, universities, funding initiatives, and a cultural vibrancy that's often missing from capital life. Manchester's Sister innovation district, backed by a £1.7bn investment, exemplifies the regional drive to build world-class environments that nurture start-ups without the London price tag. It's a place where businesses can tap into highly skilled talent, access cutting-edge research, and connect with suppliers and partners - all while enjoying a quality of life that fosters focus and creativity. This shift is also supported by the reality of modern connectivity. The ability to travel to London in a matter of hours, combined with digital tools that facilitate remote working and global outreach, means start-ups no longer need to choose between presence and opportunity. London remains a powerhouse - a city of ideas, capital and unmatched density - but it's no longer the only game in town. For founders like Lowe, Stella and Morgan-Trimmer, Manchester offers something different: space to think, room to grow, and a community that prizes collaboration over competition. The shift isn't about turning away from the capital, but expanding the idea of where innovation can thrive. As start-ups flourish beyond the old postcode boundaries, one thing is becoming clear: the future of UK entrepreneurship is not about choosing between London and elsewhere - it's about making both work, on your own terms. While some London insiders may still view the capital as the only place for innovation, the stories of Lowe, Stella, and Morgan-Trimmer highlight a broader truth: success is no longer about geography alone, but about mindset, community, and strategic choice. "Our results speak louder than our location," Lowe adds.
Yahoo
an hour ago
- Yahoo
UK MHRA Approves ImmunityBio's ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
ANKTIVA, a first-in-class, lymphocyte-stimulating agent, works synergistically with BCG to activate and proliferate natural killer (NK) and T cells, helping eliminate cancer Already approved in the U.S. and designated as a Breakthrough Therapy by the FDA, this marks ANKTIVA's first marketing approval outside the U.S. ANKTIVA plus BCG offers a new option for eligible patients among the 16,400 to 18,000 people diagnosed with NMIBC in the UK each year1 CULVER CITY, Calif., July 08, 2025--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) for the treatment of certain bladder cancer patients. This is the first marketing approval outside the U.S. for this novel lymphocyte-stimulating agent. "With the MHRA's authorization of ANKTIVA plus BCG, we can now offer our immunotherapy outside the U.S. to help patients with a disease that, if not effectively treated, can lead to bladder removal," said Dr. Patrick Soon-Shiong, Founder, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio. "This immune-boosting, lymphocyte-stimulating agent, the first of its kind, is central to our Cancer BioShield platform, which is designed to restore immune function and support long-term disease control." "ImmunityBio is honored to have received this important authorization from the UK MHRA. In light of the United States Most-Favored-Nation Prescription Drug Pricing policy implemented on May 12, 2025, we are actively evaluating our go-to-market strategy for the UK," said Richard Adcock, CEO and President of ImmunityBio. ANKTIVA is a first-in-class IL-15 agonist that activates and proliferates natural killer (NK) cells and CD4+ and CD8+ T cells. It is designed to restore immune competence by reversing lymphopenia—a condition in which cancer and conventional therapies, such as chemotherapy, radiation and checkpoint inhibitors, reduce the number and function of immune cells. Restoring immune function is essential for immunosurveillance, immunogenic cell death, and sustained tumor control. The BioShield platform's effectiveness can be monitored using a routine complete blood count (CBC). ANKTIVA was designated a Breakthrough Therapy by the FDA and received approval from both the FDA and MHRA based on its safety and efficacy outcomes of complete response (CR) and duration of response (DOR). In a single-arm, multicenter trial, 77 evaluable patients received ANKTIVA with BCG for up to 37 months. As of the November 2023 data cutoff, the duration of complete response for some patients exceeded 47 months and remains ongoing. These extended duration of complete responses beyond 24 months with ANKTIVA and BCG surpasses the benchmark for meaningful clinical results set by experts from the International Bladder Cancer Group. ImmunityBio has also submitted regulatory applications to the European Medicines Agency (EMA) to expand availability of ANKTIVA across the 27 European Union (EU) member states, as well as Iceland, Norway and Liechtenstein. About NMIBC CIS Bladder cancer is the 10th most commonly-diagnosed cancer globally,2 and in the UK, the Action Bladder Cancer UK estimates approximately 23,000 patients are diagnosed annually.1 At the time of diagnosis, about 80% of cases are non-muscle invasive bladder cancer (NMIBC), wherein the cancer is found only on the inner layer of the bladder wall.3 The standard therapy for NMIBC is intravesical instillation (delivery to the bladder via a catheter) of Bacillus Calmette-Guerin (BCG).4,5 BCG is a benign bacteria that induces an immune response in the bladder in proximity to the cancer cells, leading to clearance of the cancer in many patients. In ~30-40% of patients, however, BCG will fail, and in ~50% that initially respond, cancer will recur.6 About ANKTIVA The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved in killing cancer cells. By activating NK cells, ANKTIVA overcomes the tumor escape phase of clones resistant to T cells and restores memory T cell activity with resultant prolonged duration of complete response. ANKTIVA is a first-in-class IL-15 agonist IgG1 fusion complex, consisting of an IL-15 mutant (IL-15N72D) fused with an IL-15 receptor alpha, which binds with high affinity to IL-15 receptors on NK, CD4+, and CD8+ T cells. This fusion complex of ANKTIVA mimics the natural biological properties of the membrane-bound IL-15 receptor alpha, delivering IL-15 by dendritic cells and drives the activation and proliferation of NK cells with the generation of memory killer T cells that have retained immune memory against these tumor clones. The proliferation of the trifecta of these immune killing cells and the activation of trained immune memory results in immunogenic cell death, inducing a state of equilibrium with durable complete responses. ANKTIVA has improved pharmacokinetic properties, longer persistence in lymphoid tissues, and enhanced anti-tumor activity compared to native, non-complexed IL-15 in-vivo. ANKTIVA was approved by the FDA in 2024 for BCG-unresponsive non-muscle invasive bladder cancer CIS with or without papillary tumors. For more information, visit INDICATION AND IMPORTANT SAFETY INFORMATION FROM THE FDA LABEL INDICATION AND USAGE: ANKTIVA is an interleukin-15 (IL-15) receptor agonist indicated with Bacillus Calmette-Guerin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. WARNINGS AND PRECAUTIONS: Risk of Metastatic Bladder Cancer with Delayed Cystectomy. Delaying cystectomy can lead to the development of muscle invasive or metastatic bladder cancer, which can be lethal. If patient with CIS do not have a complete response to treatment after a second induction course of ANKTIVA with BCG, reconsider cystectomy. DOSAGE AND ADMINISTRATION: For lntravesical Use Only. Do not administer by subcutaneous or intravenous routes. Instill intravesically only after dilution. Total time from vial puncture to the completion of the intravesical instillation should not exceed 2 hours. USE IN SPECIFIC POPULATIONS: Pregnancy: May cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception. ADVERSE REACTIONS: The most common (≥15%) adverse reactions, including laboratory test abnormalities, are increased creatinine, dysuria, hematuria, urinary frequency, micturition urgency, urinary tract infection, increased potassium, musculoskeletal pain, chills and pyrexia. For more information about ANKTIVA, please see the Full Prescribing Information at You are encouraged to report negative side effects of prescription drugs to FDA. Visit or call 1-800-332-1088. You may also contact lmmunityBio at 1-877-ANKTIVA (1-877-265-8482) About ImmunityBio ImmunityBio is a vertically-integrated biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The Company's range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates natural killer cells, T cells, and memory T cells for a long-duration response. The Company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases. For more information, visit (Founder's Vision) and connect with us on X (Twitter), Facebook, LinkedIn, and Instagram. References: Action Bladder UK. Non-muscle invasive bladder cancer. May 2021. Available at: World Cancer Research Fund. Bladder Cancer Statistics. 2022. Available at: Aldousari S, Kassouf W. Update on the management of non-muscle invasive bladder cancer. Canadian Urological Association Journal, 4(1), 56–64. Holzbeierlein J, Bixler BR, Buckley DI, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline: 2024 amendment. J Urol. 2024;10.1097/JU.0000000000003846. Grabe-Heyne, et al. Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs. Front Oncol. 2023 Jun 2;13:1170124. doi: 10.3389/fonc.2023.1170124. Kodera A, Mohammed M, Lim P, Abdalla O, Elhadi M. The Management of Bacillus Calmette-Guérin (BCG) Failure in High-Risk Non-muscle Invasive Bladder Cancer: A Review Article. Cureus. 2023 Jun 26;15(6):e40962. doi: 10.7759/cureus.40962. PMID: 37503461; PMCID: PMC10369196. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding clinical trial data and potential results and implications to be drawn therefrom, the belief that the MHRA authorization leads to increased revenue, the expectation that the EAP as previously reported will enable access to ANKTIVA for patients across all solid tumor types who have exhausted first-line therapy including chemo, radiation or immunotherapy, the RMAT designation as previously reported and potential results therefrom and regulatory submissions in connection therewith, the belief that ALC levels and NLR levels obtained from a CBC are predictors of clinical benefit and outcomes relating to overall survival, the belief that improving ALC levels and NLR levels correlates with enhanced overall survival and clinical benefit, the belief that reversal of lymphopenia correlates with improved survival, clinical trial and expanded access program enrollment, data and potential results to be drawn therefrom, anticipated components of ImmunityBio's Cancer BioShield platform, the development of therapeutics for cancer and infectious diseases, potential benefits to patients, potential treatment outcomes for patients, the described mechanism of action and results and contributions therefrom, potential future uses and applications of ANKTIVA alone or in combination with other therapeutic agents for the prevention or reversal of lymphopenia, potential future uses and applications of ANKTIVA alone or in combination with other therapeutic agents across multiple tumor types and indications and for potential applications beyond oncology, potential regulatory pathways and the regulatory review process and timing thereof, the application of the Company's science and platforms to treat cancers or develop cancer vaccines, immunotherapies and cell therapies that has the potential to change the paradigm in cancer care, and ImmunityBio's approved product and investigational agents as compared to existing treatment options, and the impact of the MHRA on the Company's ex-United States go to market strategy, including in light of the recently implemented United States Most Favored Nation pricing policy on the Company's go-to-market strategy in the United Kingdom, among others. Statements in this press release that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as "anticipates," "believes," "continues," "goal," "could," "estimates," "scheduled," "expects," "intends," "may," "plans," "potential," "predicts," "indicate," "projects," "is," "seeks," "should," "will," "strategy," and variations of such words or similar expressions. Statements of past performance, efforts, or results of our preclinical and clinical trials, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio's management as well as assumptions made by and information currently available to ImmunityBio. Such information may be limited or incomplete, and ImmunityBio's statements should not be read to indicate that it has conducted a thorough inquiry into, or review of, all potentially available relevant information. Such statements reflect the current views of ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) risks and uncertainties regarding the FDA regulatory submission, filing and review process and the timing thereof, (ii) risks and uncertainties regarding regulatory submissions in foreign jurisdictions, filing and review process and the timing thereof, (iii) whether the RMAT designation will lead to an accelerated review or approval, of which there can be no assurance, (iv) risks and uncertainties regarding commercial launch execution, success and timing, (v) risks and uncertainties regarding participation and enrollment and potential results from the expanded access clinical investigation program described herein, (vi) whether clinical trials will result in registrational pathways and the risks, (vii) whether clinical trial data will be accepted by regulatory agencies, (viii) the ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs through itself and/or its investigators, and the timing and success of any such continued preclinical and clinical development, patient enrollment and planned regulatory submissions, (iv) potential delays in product availability and regulatory approvals, (x) ImmunityBio's ability to retain and hire key personnel, (xi) ImmunityBio's ability to obtain additional financing to fund its operations and complete the development and commercialization of its various product candidates, (xii) potential product shortages or manufacturing disruptions that may impact the availability and timing of product, (xiii) ImmunityBio's ability to successfully commercialize its approved product and product candidates, (xiv) ImmunityBio's ability to scale its manufacturing and commercial supply operations for its approved product and future approved products, and (xv) ImmunityBio's ability to obtain, maintain, protect, and enforce patent protection and other proprietary rights for its product candidates and technologies. More details about these and other risks that may impact ImmunityBio's business are described under the heading "Risk Factors" in the Company's Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 3, 2025, and the Company's Form 10-Q filed with the SEC on May 12, 2025, and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC's website at ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. View source version on Contacts ImmunityBio Contacts: Investors Hemanth Ramaprakash, PhD, MBA ImmunityBio, Inc. +1 Media Sarah Singleton ImmunityBio, Inc. +1 Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
First tranche of final report from Horizon scandal inquiry to be published
The first tranche of the long-awaited final report from an inquiry into the Post Office Horizon scandal is set to be published. More than 900 subpostmasters were wrongfully prosecuted by the Post Office between 1999 and 2015 in what has been dubbed as the worst miscarriage of justice in British legal history. Many were wrongly convicted of crimes such as theft and false accounting after faulty Horizon software made it look as though money was missing from their accounts. Subpostmasters' lives were destroyed – with some bankrupted by legal action and sent to prison. On Tuesday, the first volume of the Horizon IT inquiry's final report will be published – covering the devastating impact on the lives of the scandal's victims and the compensation process. The issue of financial redress has frequently been flagged as an issue by subpostmasters – with many still awaiting full compensation. The various compensation schemes have been criticised by victims as unfair and difficult to navigate – processes which lead campaigner Sir Alan Bates has previously described as 'quasi-kangaroo courts'. Retired judge Sir Wyn Williams, the chairman of the probe, will make a public statement following the report's publication. The inquiry was established in 2020, with a number of witnesses giving evidence on the use of Fujitsu's Horizon system, Post Office governance and the legal action taken against subpostmasters. In a previous statement addressing the compensation schemes, the Department for Business and Trade said: 'This Government has quadrupled the total amount paid to affected postmasters to provide them with full and fair redress, with more than £1 billion having now been paid to over 7,300 claimants.'
